Alivus Life Sciences Ltd Share Price & Stock Analysis

Alivus Life Sciences Ltd (NSE: ALIVUS, BSE: 543322) is a Mumbai, Maharashtra-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹17,862 Cr, it ranks #392 by market cap among the 6,197 Indian listed companies on FinBizNet, and #3 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹1,464.00 (as of 16 Nov 2026), the share price is 7.0% below its 52-week high of ₹1,574.00 and 78.8% above its 52-week low of ₹819.00. The share price is up 64.0% over one year and up 6.3% over three months.

Key Metrics

Current Price₹1,464.00
Market Cap₹17,862 Cr
NSE SymbolALIVUS
BSE Code543322
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryPharmaceuticals > Pharmaceutical Contract Manufacturing Services
P/E Ratio31.5
Return on Equity18.36%
Return on Assets12.21%
52-Week Range₹819.00 – ₹1,574.00
1-Year Price Change+64.0%
3-Month Price Change+6.3%
Beta (1Y)0.29
Dividend Yield0.35%
HeadquartersMumbai, Maharashtra
Websitewww.alivus.com

Latest Quarterly Results — Q2 FY27

Revenue₹682 Cr
Net Profit₹197 Cr
Net Margin28.8%
EPS (Basic)₹16.02
Basisstandalone

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Alivus Life Sciences Ltd Quarterly Revenue and Profit Trend

Alivus Life Sciences Ltd reported revenue of ₹682 Cr in Q2 FY27, up 16.0% from ₹588 Cr in Q2 FY26 and up 6.5% from ₹640 Cr in Q1 FY27. It posted a net profit of ₹197 Cr for the quarter, against a net profit of ₹130 Cr in Q2 FY26 (up 51.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹588 Cr (Q2 FY26) to ₹689 Cr (Q4 FY26). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹682 Cr₹197 Cr28.8%
Q1 FY27₹640 Cr₹160 Cr25.0%
Q4 FY26₹689 Cr₹163 Cr23.6%
Q3 FY26₹673 Cr₹150 Cr22.3%
Q2 FY26₹588 Cr₹130 Cr22.1%
Q1 FY26₹602 Cr₹122 Cr20.2%
Q4 FY25₹650 Cr₹142 Cr21.8%

Standalone figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 74.85% of Alivus Life Sciences Ltd's shares as of Sept 2026, against 74.91% in Sept 2025 (−0.06 percentage points). Delivery averaged 50.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 a

Products and Services

1. Active Pharmaceutical Ingredient (API)-This segment develops and manufactures non-commoditized active pharmaceutical ingredients for various chronic therapeutic, gastro-intestinal disorder, anti-infective, and other therapeutic areas. 2. Other Operating Revenue-This segment develops and manufactures active pharmaceutical ingredients in chronic therapeutic areas, such as cardiovascular disease, central nervous system disease, pain management, and diabetes. 3. CDMO-This segment provides CDMO services to a range of multinational and specialty pharmaceutical companies. 4. Generic API-NA

Business Segments

1. Active Pharmaceutical Ingredient (API)-100%

Alivus Life Sciences Ltd vs Peers — Pharmaceutical Contract Manufacturing Services

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Torrent Pharma Ltd.₹1,79,494 Cr73.616.98%₹4,979 Cr+30.4%
Aether Industries Limited₹21,710 Cr101.89.81%₹347 Cr+127.8%
Alivus Life Sciences Ltd₹17,862 Cr31.518.36%₹682 Cr+64.0%
Aarti Pharmalabs Ltd₹8,374 Cr52.58.49%₹610 Cr+15.4%
Solara Active Pharma Sciences Limited₹3,225 Crn/m-0.63%₹417 Cr+22.1%
Sai Parenteral's Limited₹2,235 Cr115.82.88%₹195 Cr—
KRM Ayurveda Limited₹521 Cr25.917.54%₹32 Cr—
Trident Lifeline Limited₹511 Cr26——+37.6%
Infinium Pharmachem Limited₹436 Cr36.410.54%—+11.7%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Alivus Life Sciences Ltd?

Alivus Life Sciences Ltd is trading at ₹1,464.00, with a market capitalisation of ₹17,862 Cr.

Which sector does Alivus Life Sciences Ltd belong to?

Alivus Life Sciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).

What are the key financial ratios of Alivus Life Sciences Ltd?

Alivus Life Sciences Ltd has a P/E of 31.5 and a return on equity of 18.36%.

What is the stock symbol of Alivus Life Sciences Ltd?

Alivus Life Sciences Ltd is listed on the NSE under the symbol ALIVUS and on the BSE under the scrip code 543322.

How has Alivus Life Sciences Ltd's share price moved over the past year?

Alivus Life Sciences Ltd's share price is up 64.0% over one year and up 6.3% over three months. Its 52-week range is ₹819.00 to ₹1,574.00.

What were Alivus Life Sciences Ltd's latest quarterly results?

In Q2 FY27, Alivus Life Sciences Ltd reported revenue of ₹682 Cr and net profit of ₹197 Cr, with basic EPS of ₹16.02 (standalone, parsed from the company's exchange filing).

How have Alivus Life Sciences Ltd's revenue and profit changed over the past year?

Alivus Life Sciences Ltd reported revenue of ₹682 Cr in Q2 FY27, up 16.0% from ₹588 Cr in Q2 FY26 and up 6.5% from ₹640 Cr in Q1 FY27.

What is the promoter holding in Alivus Life Sciences Ltd?

Promoters held 74.85% of Alivus Life Sciences Ltd's shares as of Sept 2026, against 74.91% in Sept 2025 (−0.06 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.